OXB.LSE Oxford BioMedica PLC

Healthcare Biotechnology London Exchange
5.45 GBX
Close of Nov 3, 2026
420.00 962.00
Market cap
GBX 662M
P/E
-
P/B
11.09x
ROE
-254.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is OXB.LSE undervalued?

Graham number

The Graham number of Oxford BioMedica PLC cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Oxford BioMedica PLC fundamental analysis

No fundamental analysis for Oxford BioMedica PLC yet.

Oxford BioMedica PLC stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Oxford BioMedica PLC

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems; InAAVate, a proprietary "plug and play' dual-plasmid system for transient transfection, as well as a standard triple transfection system for AA…

Full company profile